BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA

The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.

Businessman touched r and d sign. R d icon network business concept word cloud background tag. R&D: Research and development word lettering typography design illustration with line icons and ornaments
Pfizer and BioNTech announced their third vaccine deal, for an mRNA shingles vaccine • Source: Shutterstock

While the enormous financial windfalls from COVID-19 vaccines and drugs have led to market speculation of a new wave of mergers and acquisitions in 2022, the huge revenues have also yielded investment in existing pipelines. Pfizer Inc. and BioNTech SE’s 5 January announcement they are developing a shingles vaccine is a case in point.

This is the third in a series of vaccine-development partnerships between the companies around BioNTech’s messenger RNA technology, after one...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category